31.4400.45% ( +0.140 )
Closed: Nov 11, 15:59:58 (EDT)Current ValuationThe current P/E ratio is -60.12, below the reasonable range, cheaper than 92.31% of the time in the past 1 years, and the industry ranks 543/606, the industry Median -1.82.
-60.12xP/E
$31.30Stock price
$-0.52Earnings per share
-60.12xP/E
Stock price$31.30Earnings per share$-0.52
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -53.01x
- Typical range
- -58.31x–-48.38x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -54.88x | 162.77% | $211.94B |
MRNAUSModerna | -35.91x | 1.52% | $100.14B |
CSLLYUSCSL Limited | -25.59x | -- | $65.99B |
NTRAUSNatera | -274.65x | 0.99% | $45.24B |
RVMDUSRevolution Medicines | -22.12x | 40.80% | $41.38B |
ROIVUSRoivant Sciences | -86.67x | 67.79% | $29.84B |
INSMUSInsmed | -43.28x | 74.47% | $26.21B |
BNTXUSBioNTech SE | -12.78x | 29.90% | $21.62B |
BBIOUSBridgebio Pharma | -25.88x | 30.83% | $15.32B |
SMMTUSSummit Therapeutics | -17.08x | 23.12% | $14.22B |
KYMRUSKymera Therapeutics | -32.52x | 8.74% | $11.36B |
BMRNUSBioMarin Pharma | -578.91x | 56.09% | $11.07B |
PCVXUSVaxcyte | -9.15x | 44.27% | $10.50B |
MDGLUSMadrigal Pharma | -64.64x | 87.15% | $10.05B |
SYREUSSpyre Therapeutics | -44.30x | 59.92% | $9.92B |
PRAXUSPraxis Precision Medicines | -26.22x | 0.57% | $9.43B |
TWSTUSTwist Bioscience | -63.62x | 32.38% | $8.70B |
RYTMUSRhythm Pharma | -39.84x | 51.65% | $7.90B |
CYTKUSCytokinetics | -10.06x | 8.57% | $7.83B |
ALKSUSAlkermes | -22,247.82x | 134.90% | $7.81B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
